Literature DB >> 14559093

Passive immunization as prophylaxis: when and where will this work?

Paul M Dunman1, Mirjana Nesin.   

Abstract

The strict definition of passive immunoprophylaxis includes the administration of exogenously produced antibodies (polyclonal and monoclonal) to prevent infections in exposed individuals, inactivate bacterial toxins or "correct" hypogammaglobulinemia in immunocompromised hosts. This definition can be broadened to include modulators of the immune system. Despite advances in chemotherapy and vaccine development, suitable treatment is not currently available for many pathogens. As a result, passive immunization is an appropriate therapeutic option for many organisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559093     DOI: 10.1016/j.coph.2003.05.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  7 in total

1.  Targeting pili in enterococcal pathogenesis.

Authors:  Kenneth L Pinkston; Kavindra V Singh; Peng Gao; Nathaniel Wilganowski; Holly Robinson; Sukhen Ghosh; Ali Azhdarinia; Eva M Sevick-Muraca; Barbara E Murray; Barrett R Harvey
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

Review 2.  Status of contraceptive vaccines.

Authors:  Rajesh K Naz
Journal:  Am J Reprod Immunol       Date:  2009-01       Impact factor: 3.886

Review 3.  Development of genetically engineered human sperm immunocontraceptives.

Authors:  Rajesh K Naz
Journal:  J Reprod Immunol       Date:  2009-10-23       Impact factor: 4.054

Review 4.  Vaccine for human contraception targeting sperm Izumo protein and YLP12 dodecamer peptide.

Authors:  Rajesh K Naz
Journal:  Protein Sci       Date:  2014-04-22       Impact factor: 6.725

5.  Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development.

Authors:  A S Samuel; R K Naz
Journal:  Hum Reprod       Date:  2008-03-26       Impact factor: 6.918

Review 6.  Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.

Authors:  Tharmala Tharmalingam; Xiaobing Han; Ashley Wozniak; Laura Saward
Journal:  Hum Vaccin Immunother       Date:  2021-05-19       Impact factor: 4.526

7.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.